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1. Introduction 
Since its inception in 1989/1990, the Human Genome Proj-
ect has put major emphasis on structural genome analyses, 
resulting in elaborate genetic and physical maps. As a result 
of these achievements, important disease genes have been 
identified through positional cloning, and the focus of the 
project is now turning toward sequencing the entire genome. 
Complete sequences of genome DNA have already been de-
termined for several single cell organisms [1-3] including Sac-
charomyces cerevisiae (yeast) [4], and vigorous analyses are 
being carried out on many other organisms [5,6]. Sequencing 
the human genome is expected to be complete around the year 
2005. 
The goal of genome analysis is to decode the entire genetic 
information carried in the genome. This means that, besides 
sequencing, information which cannot readily be read from 
structural data must be collected. Examples are the activities 
of hypothetical gene products, the expression control and the 
regulatory network of each gene. This requires systematic ef-
forts which may be collectively called functional analysis of 
the genome. In this connection, a consortium has been estab-
lished for functional analysis of the S. cerevisiae genome 
through systematic disruption of genes [7] 
For higher eukaryotes with more genes, however, different 
strategies are needed, such as enlisting all (or nearly all) the 
active genes and studying the sites of their expression together 
with the extent of their activities. A list of active genes and 
their activities in the cells and tissues can be called an expres-
sion profile. Construction of such a list should be started with 
the representative cells or tissues of the body and expanded to 
cover the various stages of development or pathological con-
ditions. 
2. Expression profiles 
Kohara et al. have initiated the collection of large numbers 
of in situ staining patterns with Caenorhabditis elegans, using 
probe cDNAs that represent novel genes as discovered by 
single run cDNA sequencing. This worm is transparent and 
is composed of only 965 cells, thus allowing for whole body 
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analysis [8,9]. The facts that cell lineages are well established 
during development and that there is only a small number of 
genes for testing favor adoption of this procedure. 
In the case of man, body size and the large number of genes 
preclude a similar approach. Thus, Okubo et al. have initiated 
efforts to identify active genes by single pass sequencing of 
cDNA obtained from a type of cell or tissue and quantified 
their activities in the mRNA population [10]. Although an 
adult human body consists of some 6 trillion cells, they can 
be categorized into 200 basic types [11]. Therefore, the num-
ber of cells or tissue species is within a reasonable range. 
The cDNA libraries used by these authors contain only the 
3' terminal restriction fragments [12]. They were not amplified 
prior to the experiments so that they faithfully represent the 
composition of mRNA in the cellular source. In addition, care 
has been taken that the source materials are prepared to be as 
homogeneous as possible by using well-characterized cell lines 
[13], selective primary culturing [14], and purification with 
antibodies or through careful dissection [15]. The clones in 
the libraries were randomly selected and sequenced for iden-
tifying the genes and for measuring the abundance of their 
transcripts. Although they carry little amino acid sequence 
information, the 3' sequences correspond to the respective 
genes, and are termed gene signatures (GS) [16]. The resulting 
lists, showing active genes and their relative activities, are 
called expression profiles, and some of these (parts of the 
profiles) are shown in Table 1. 
3. Body map and ESTs 
By compiling expression profiles from different parts of the 
body, the cells or tissues where any given gene is active can be 
identified. As genes are mapped in the body where they are 
active, this data set is called a 'Bodymap' (http://www.imcb.o-
saka-u.ac.jp/bodymap) [10,17]. As of June 1996, about 13 000 
genes have been mapped on the body. A part of the bodymap 
which focuses on genes encoding cytoskeletal proteins is 
shown in Table 2. 
In addition to the bodymap, there are two major collections 
of partial cDNA sequences, collectively called EST (expressed 
sequence tags), which are compiled in a dbEST (http:// 
www.ncbi.nlm.nih.gov/dbEST) [18]. One set, constructed in 
order to identify new genes of commercial interest, consists 
of 174000 ESTs from randomly primed cDNA fragments or 
the 5' ends of conventional cDNAs of human organs [19] (for 
further references, see [20]). In this data set, several sequences 
from different regions of a single mRNA are collected indis-
criminately. Another set containing some 280000 ESTs [21] 
has been constructed to obtain probes for gene mapping [22]. 
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Table 1 
Expression profiles of active genes in the adult liver [30], lung [31] and colon mucosa [32] 
Adult liver 
GS# 
364 
2085 
2174 
476 
2155 
277 
196 
2176 
2541 
111 
2093 
2047 
2092 
2116 
2148 
2202 
2525 
732 
1766 
2120 
285 
380 
689 
934 
1305 
2075 
2105 
2152 
2423 
2564 
f 
140 
34 
16 
13 
10 
9 
8 
7 
7 
6 
6 
5 
5 
5 
5 
5 
5 
4 
4 
4 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
Gene name 
serum albumin 
haptoglobin alpha IS 
a-1 acid glycoprotein 
apolipoprotein B 
transferrin 
apolipoprotein All 
fatty acid binding protein 
apolipoprotein C-II 
P-450 S-mephenytoin 
4-OHase 
al-antitrypsin 
aldolase B 
gamma fibrinogen 
retinol binding protein 
alcohol dehydrogenase ß-1 
cx-2-macroglobulin 
fibrinogen ß-chain 
prothrombin (F2) 
ribosomal protein L38 
metallothionein 
fibrinogen ß-chain (short 
3'UTR) 
ribosomal protein L21 
coxVIb 
vacuolar H + ATPase 
inter-a trypsin inhibitor 
fibronectin 
complement component C4A 
Lung 
GS# 
2894 
2842 
937 
2105 
211 
314 
2148 
1657 
292 
2542 
1671 
1720 
1929 
689 
293 
1791 
583 
1189 
114 
335 
708 
1367 
1382 
1786 
1891 
1919 
2025 
2656 
2702 
2728 
f 
67 
30 
11 
9 
5 
5 
4 
4 
4 
4 
4 
4 
4 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
Gene name 
pulmonary surfactant 
Clara cell protein 
HLA-E heavy chain 
fibronectin 
ribosomal protein S8 
ribosomal protein SII 
cc-2-macroglobulin 
ribosomal protein LI8 
ribosomal protein S16 
immunoglobulin 1 chain 
protein p68 
lipocortin II 
ribosomal protein L27a 
ubiquitin 
ribosomal protein L3 
y-actin 
ribosomal protein L7a 
ribosomal protein L29 
hnRNP-El 
B4B 
calcyclin 
MHC class II antigen 
c-fos 
Colon 
GS# 
196 
2546 
4094 
2542 
2706 
2123 
4116 
335 
223 
650 
1809 
1766 
285 
273 
1657 
162 
155 
19 
565 
917 
1670 
211 
96 
304 
932 
2073 
2673 
1404 
244 
4070 
mucosa 
f 
37 
18 
13 
11 
11 
11 
9 
6 
6 
6 
6 
5 
5 
5 
4 
4 
4 
4 
4 
4 
4 
3 
3 
3 
3 
3 
3 
3 
3 
3 
Gene name 
fatty acid binding protein 
immunoglobulin X light chain 
CD24 signal transducer 
carcinoma antigen GA733-2 
ribosomal protein L7a 
cytokeratin 8 
ribosomal protein S18 
lysosomal glycoprotein CD63 
metallothionein 
ribosomal protein L21 
tumor protein 
ribosomal protein LI8 
ribosomal phosphoprotein P2 
thymosin ß-4 
elongation factor 1-a 
ß-2-microglobulin 
ribosomal protein S8 
alpha NAC 
ubiquitin 
succinate dehydrogenase 
set 
ß-actin 
carcinoembryonic antigen 
Gene signatures (GS) that identify genes, composition of mRNA (f : frequency of appearance expressed per mil.), and the names of the genes are 
shown. Blanks under 'gene name' indicate novel genes. For purposes of clarity only the 30 most active genes are shown. 
The majority of the source cDNA libraries for this work were 
'normalized' in vitro in order to reduce the number of abun-
dant, frequently appearing clones [23]. Regardless of the orig-
inal purpose of construction, these data sets are useful gene 
pools for 'fishing' new members of gene families or human 
orthologs of genes of other species, because they contain a 
significant number of entries [24,25]. 
In Table 3, distributions of ESTs among the human organs 
are shown. The same set of cytoskeletal gene transcripts as in 
Table 2 were selected for comparison. In accordance with the 
results in Table 2, actins and tubulins are distributed among a 
variety of tissues, as is already well known. Notice, however, 
that the multiple appearance of these gene transcripts in EST 
collections simply reflects incomplete normalization of the li-
braries, whereas those in the bodymap represent their gene 
activities. The high expression of tubulins in fetal neurons 
and fibroblasts, or the clear division of the site of cytokeratin 
gene expression into simple and stratified epithelial types, can 
be seen only in the bodymap because the histological resolu-
tion of gene expressions has been pursued. Overall, the dbEST 
should be regarded as a part of structural data, rather than 
functional data of the human genome. 
As the number of genes collected and tissues analyzed in the 
bodymap is not yet large enough (the gene coverage is about 
one fourth of the dbEST), its usefulness remains limited. For 
this reason, a high throughput sequencing system is urgently 
needed. As a compromise, a method called SAGE has been 
proposed, in which 9 bp tags, resected from defined positions 
of cDNAs, are tandemly ligated and sequenced [26]. 
Methods other than nucleotide sequencing can also be em-
ployed for identifying active genes. Kato [27] has described 
'molecular indexing', using the size of a restriction fragment 
of cDNA as an identifier : the cDNAs are cleaved by a type 
IIS enzyme and subjected to 64 different adapter-mediated 
PCRs. Altogether, 256 groups of the amplification products 
from a library have been fractionated in sequencing gels. By 
repeating this procedure with a few type IIS enzymes, most of 
the transcripts in source cells are displayed separately in the 
gel, one gene transcript being represented by a band of unique 
size, and its abundance by the band intensity. Another emerg-
ing technique is construction of arrays of oligonucleotides or 
unique fragments of cDNA at high density on solid support, 
which can be hybridized with uniformly labeled mRNA or 
cDNA [28,29], for detection of active genes and their relative 
activities by their intensities. At the moment, however, specif-
icity and sensitivity are the problems, since hybridization pa-
rameters differ from sequence to sequence. 
4. Conclusion 
An average higher eukaryotic cell carries some 10000 spe-
cies of gene transcripts, and the total number of mRNA mol-
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Acc#, accession number in GenBank. For other definitions, see Table 1. Entries for human actins, tubulins, cytokeratins, and representative neural 
intermediate filaments were culled from Swiss Prot and a cDNA or a gene sequence corresponding to each of them in GenBank/EMBL was 
compared with Gene Signatures (GS) using the FastA program [33]. GS with bases more than 90% identical to those of the cDNAs or gene 
sequences were counted. Genes for cytokeratins 1, 2, 9, 10, 11, 12, and 20 were not found among either GS or ESTs (see Table 3). 
'Temporal lobes from an age matched pair of normal brain (1) and the brain of an Alzheimer disease patient (2). 
ecules is estimated to be several hundreds of thousands. Ex-
pression profiling, by sequencing or by other means, to de-
scribe the composition of these mRNA populations provides 
the basis for future functional analyses of the genome. The 
method established for the global description of gene expres-
sion control and gene networks can be extended to a variety 
of other systems and organisms. Some of the expected appli-
cations may include sorting novel genes that are defined as cell 
or tissue specific and studying their possible medical, diagnos-
tic and pharmaceutical applications. Obtaining markers for 
monitoring cell differentiation or detecting pathological 
changes of gene activities in cells for diagnostic purposes 
may be other interesting examples of the application of this 
method. 
There is a great need for two major technological develop-
ments : high throughputs, as noted in the text, and down-scal-
ing the analysis to a single cell level. Even though the system 
is still far from being technologically mature, the importance 
of the project demands enriching the databases in order to 
achieve the goal of describing how the approximately 
100000 genes in the human genome act in concert in the 
regulation of the whole body. Collaboration towards this 
goal is of crucial importance. 
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